Efficacy and safety of switching to flumatinib in patients with chronic myeloid leukemia who have not achieved optimal response or are intolerant to TKI treatment
10.16016/j.2097-0927.202310076
- VernacularTitle:慢性髓系白血病慢性期TKI治疗未达最佳反应或不耐受患者转换氟马替尼的有效性和安全性临床观察
- Author:
Songfan YANG
1
,
2
;
Qin WEN
;
Ying ZHANG
;
Jinglong LYU
;
Hua'e SHU
;
Hongju YAN
;
Cheng ZHANG
;
Jin WEI
;
Xi ZHANG
Author Information
1. 637002 南充,川北医学院附属医院血液科
2. 400037 重庆,陆军军医大学(第三军医大学)第二附属医院血液病医学中心,全军临床重点专科,创伤与化学中毒全国重点实验室,重庆市临床重点专科,血液病与微环境重庆市重点实验室
- Keywords:
chronic myeloid leukemia;
BCR-ABL positive;
TKI;
flumatinib
- From:
Journal of Army Medical University
2024;46(4):340-346
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of flumatinib conversion in chronic myelogenous leukemia-chronicphase(CML-CP)patients with suboptimal TKI response or intolerance.Methods Patients who did not have the best response or intolerance to first-line imatinib,dasatinib,and nilotinib and switched to flumatinib(600 mg/d)from February 2020 to August 2022 were collected from 5 hospitals from Chongqing and affiliated hospitals of North Sichuan Medical College.The efficacy and safety of flumatinib were observed.The optimal response rate,major molecular response(MMR),cumulative complete cytogenetic response(CCyR)rate,cumulative MMR rate,cumulative deep molecular response(DMR),progression-free survival(PFS),event-free survival(EFS)and adverse reactions in 3,6 and 12 months after treatment were observed and analyzed.Results A total of 100 patients with CML-CP were enrolled,with a median follow-up of 18(3~36)months.The optimal response rate was 92.6%(88/95),94.4%(85/90)and 92.9%(79/85)respectively,at 3,6 and 12 months after treatment.Till August 20,2023,the cumulative CCyR and MMR rate was 98.0%(98/100)and 81.9%(77/94),respectively,the median time to reach CCyR and MMR was 3 months,and cumulative DMR rate was 51.0%(51/100).PFS rate was 100.0%(100/100)and 1-year EFS rate was 85.6%(75/90).The most common non-hematologic adverse reactions of flumatinib were diarrhea and abdominal pain(7.0%),followed by renal dysfunction(6.0%)and musculoskeletal pain(2.0%).The main hematologic adverse reactions were thrombocytopenia(12.0%),anemia(6.0%)and leukopenia(2.0%).Conclusion Flumatinib has better MMR and DMR and is well tolerated in CML-CP patients with TKI resistance or intolerance.